LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes
Phase 3
Completed
- Conditions
- Acute Coronary Syndromes
- Registration Number
- NCT00214630
- Lead Sponsor
- AstraZeneca
- Brief Summary
Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 825
Inclusion Criteria
- Non-ST segment elevation ACS and ST segment elevation ACS who receive optimal reperfusion therapy
Exclusion Criteria
- Previous Q-wave infarct within the last 4 weeks
- CK elevation not caused by myocardial injury
- uncontrolled hypertension at time of randomization
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Reduction of LDL-C following 12 weeks of treatment
- Secondary Outcome Measures
Name Time Method % change from baseline in LDL-C following 2 & 6 weeks of treatment; % change from baseline in TC, HDL-C, triglycerides, non-HDL-C, apolipoprotein A-1, apolipoprotein B, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, ApoB/Apo A-1 @ weeks 6 & 12
Trial Locations
- Locations (1)
Research Site
🇵🇦Panama City, Panama